Idarubicin Injection 20 mg/20 mL (3)

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

idarubicin hydrochloride, Quantity: 1 mg/mL

Disponible depuis:

Pfizer (Perth) Pty Ltd

forme pharmaceutique:

Injection, solution

Composition:

Excipient Ingredients: glycerol; hydrochloric acid; water for injections

Mode d'administration:

Intravenous

Unités en paquet:

1 x 20 mL

Type d'ordonnance:

(S1) This Schedule is intentionally blank

indications thérapeutiques:

UK: Zavedos is used in adults and children for the treatment of acute non lymphoblastic leukaemia (ANLL), also referred to as acute myeloid leukaemia (AML). Zavedos is also used in adults and children as a second line treatment of relapsed acute lymphoblastic leukaemia (ALL)

Descriptif du produit:

Visual Identification: Red - orange, clear, mobile solution; Container Type: Vial; Container Material: PP; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Statut de autorisation:

Listed (Export Only)

Date de l'autorisation:

2023-02-17